CohBar, Inc.

Equities

CWBR

US19249J3077

Biotechnology & Medical Research

Market Closed - OTC Markets 03:50:32 2024-07-19 pm EDT 5-day change 1st Jan Change
0.2405 USD +20.25% Intraday chart for CohBar, Inc. +20.25% -67.50%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Stock Futures Steady as Earnings Season Ramps Up DJ
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Samsung Warning Knocks Tech Stocks DJ
North American Morning Briefing : Stock Futures Struggle After Weak China Data DJ
North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment DJ
North American Morning Briefing : Traders Eye -2- DJ
North American Morning Briefing : China Outlook -2- DJ
CohBar, Inc.(OTCPK:CWBR) dropped from S&P TMI Index CI
North American Morning Briefing : November Rally Pauses Ahead of This Week's PCE Report DJ
CohBar, Inc.(OTCPK:CWBR) dropped from NASDAQ Composite Index CI
North American Morning Briefing : All Eyes on -2- DJ
CohBar, Inc. Announces Resignation of Jeffery F. Biunno as Chief Financial Officer CI
CohBar, Inc. Announces Resignation of Joseph J. Sarret as Chief Executive Officer CI
CohBar, Inc. Announces Executive Changes CI
Morphogenesis, Inc. cancelled the acquisition of CohBar, Inc. in a reverse merger transaction. CI
North American Morning Briefing : Focus Shifts to -2- DJ
CohBar, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Morphogenesis, Inc. and Cohbar, Inc. Announce Positive Results from Phase 1B Trial of Ifx-Hu2.0, A Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma CI
Wall Street Set to Open Lower as Investors Await Progress on Debt-Ceiling Talks Ahead of Fed Minutes Release MT
US Futures Lower as Investors Eye Debt Ceiling Talks, Await Fed Minutes Release MT
Top Premarket Decliners MT
Top Midday Gainers MT
Transcript : CohBar, Inc., Morphogenesis, Inc. - M&A Call
Morphogenesis, Inc. entered into a definitive agreement to acquire CohBar, Inc. for approximately $130 million in a reverse merger transaction. CI
Morphogenesis, Inc. announced that it expects to receive $15 million in funding from CohBar, Inc. CI
Chart CohBar, Inc.
More charts
CohBar, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.
More about the company